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Abstract: Resistance training (RT) and n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation
have emerged as strategies to improve muscle function in older adults. Overweight/obese post-
menopausal women (55–70 years) were randomly allocated to one of four experimental groups,
receiving placebo (olive oil) or docosahexaenoic acid (DHA)-rich n-3 PUFA supplementation alone
or in combination with a supervised RT-program for 16 weeks. At baseline and at end of the trial,
body composition, anthropometrical measures, blood pressure and serum glucose and lipid biomark-
ers were analyzed. Oral glucose tolerance tests (OGTT) and strength tests were also performed.
All groups exhibit a similar moderate reduction in body weight and fat mass, but the RT-groups
maintained bone mineral content, increased upper limbs lean mass, decreased lower limbs fat mass,
and increased muscle strength and quality compared to untrained-groups. The RT-program also
improved glucose tolerance (lowering the OGTT incremental area under the curve). The DHA-rich
supplementation lowered diastolic blood pressure and circulating triglycerides and increased muscle
quality in lower limbs. In conclusion, 16-week RT-program improved segmented body composition,
bone mineral content, and glucose tolerance, while the DHA-rich supplement had beneficial effects
on cardiovascular health markers in overweight/obese postmenopausal women. No synergistic
effects were observed for DHA supplementation and RT-program combination.
Keywords: postmenopause; obesity; DHA; resistance training; glucose tolerance; body composition;
lipid metabolism
1. Introduction
Menopause is a critical stage in the physiological process of aging among women,
with final menstrual period being a marker of aging and health [1], and age at menopause
influencing the risk for all-cause mortality [2]. During menopause, redistribution of fat mass
from gluteo-femoral depots towards the visceral cavity, alongside with muscle and bone
mass loss, give rise to a constellation of unfavorable metabolic conditions such as insulin
Nutrients 2021, 13, 2465. https://doi.org/10.3390/nu13072465 https://www.mdpi.com/journal/nutrients
Nutrients 2021, 13, 2465 2 of 21
resistance, unhealthy lipid profiles, abnormal glucose metabolism and decreased metabolic
rate [3]. Altogether, these circumstances mimic those of aging in a short period of time and
increase the risk of developing sarcopenic obesity, metabolic syndrome, Type 2 diabetes
mellitus, coronary heart disease and osteoporosis, which are more prevalent diseases
among post- than pre-menopausal women, and in older women than men [3–5].
On the other hand, obesity can also have a negative impact in the menopausal transi-
tion, and thus in the process of aging, as obesity itself increases the risk for such metabolic
diseases and also for frailty [6]. Although interrelationships between obesity, menopause
and aging are not established yet, several interventions have been developed with the
aim to improve health and well-being among the older, obese population. Interestingly,
some authors have described sedentary lifestyles as the main factor to affect health and
well-being in older subjects [7]. Hence, exercise training interventions have been developed,
with resistance training (RT) as a novel approach to increase muscle strength and lean mass,
with the consequent improvement in physical function and metabolic profile, together with
preventing future frailty and disability in older adults [8,9].
RT can elicit a potent neuromuscular stimulus that, when maintained on a regular
basis, is able to improve lean mass, muscle strength, bone mineral density, and physical
function also among postmenopausal women [8,10–12]. Such improvements in muscle
metabolism are the main cause for RT ability to improve glucose homeostasis in older
women [13]. However, effects on insulin resistance are yet to be elucidated, and RT has
been established to be effective in insulin resistant, but not in healthy, older subjects [13,14].
Likewise, hypotensive effects have been limited to normotensive older subjects in some
studies [15], while heterogenous effects have been highlighted for both hypertensive and
normotensive older women depending on their response to RT [16]. Concerning lipid
metabolism, some studies have revealed an effect on lowering total cholesterol (total chol)
and LDL-cholesterol (LDL-chol) while increasing HDL-cholesterol (HDL-chol) [17,18],
and others have shown neutral effects [15] or pointed out the high variability in individuals
responses to RT [19]. Body composition results are also inconclusive, and it seems that
only long periods of RT can elicit changes in fat mass and muscle mass [20], and so well
designed interventions studying RT programs have found no effects on body composition,
even when strength improvements were found [11,12,21]
Among dietary interventions, n-3 polyunsaturated fatty acids (n-3 PUFA) eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA) have been recently discovered to play
a role in muscle protein synthesis [22]. This finding has prompted the development of
interventions with both RT and n-3 PUFA in postmenopausal women [23–26]. Nevertheless,
such studies have failed to investigate n-3 PUFA combined with RT effects further than
strength gains or muscle protein synthesis. Noteworthy, DHA has been suggested to have
more beneficial effects on obesity than EPA [27,28]. Interestingly, higher DHA levels in
plasma lipids but not EPA or alpha-linolenic acid are related with lower progression of
coronary artery disease in postmenopausal women [29]. Moreover, DHA levels are higher
in pre than post-menopausal women [30] and have been demonstrated to have higher
antithrombotic effects than EPA [31]. DHA supplementation has been proved to lower
triglycerides (TG) in a dose-dependent manner in healthy postmenopausal women [32].
Although DHA effects on lowering LDL-chol have not been demonstrated in this pop-
ulation, effects on lowering small, dense LDL-chol percentage have been reported [33],
and also on increasing HDL-chol [31]. Moreover, meta-analyses have highlighted the role
of DHA and EPA on lowering blood pressure in the general population [34]. Remarkably,
DHA levels are lower also in postmenopausal Type 2 diabetes mellitus patients than in
their healthy counterparts [30], and it has been highlighted that n-3 PUFA might be effec-
tive in improving insulin sensitivity in individuals under metabolic risk [35]. However,
DHA effects in post-menopausal women are still controversial regarding insulin sensitivity,
as well-designed trials have shown no effects [36]. Regarding body composition they
seem to have no relevant effects [37] except for bone mineral density, which has been
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found to be positively associated to the n-3 PUFA content in erythrocytes in osteoporotic,
postmenopausal women [38].
Thus, the objective of this study was to examine if supplementation with a DHA-
rich fish oil concentrate and a progressive RT program, alone or in combination, for
16 weeks, could have beneficial effects on improving body composition, lipid, and glucose
metabolism biomarkers, as well as muscle strength and quality in overweight and obese
postmenopausal women.
2. Materials and Methods
2.1. Participants
A total of 124 postmenopausal women were recruited by advertisement in local
newspapers and by phone calls to volunteers from the database of the Metabolic Unit
(MU) of the University of Navarra. The inclusion criteria were being 55–70 years old
and overweight II/obese Type I (BMI of 27.5–35 kg/m2), with a stable weight in the last
3 months (±3 kg) and an overall physical and physiological condition in accordance with
the aim of the study (i.e., not suffering from musculoskeletal injuries that limited the subject
performance during the RT program). Exclusion criteria for enrolment were as follows: use
of some regular prescription medication, including hormonal therapy, oral antidiabetic
drugs, hypolipidemic drugs, and proton pump inhibitors. Antihypertensive therapy,
thyroid hormones, anxiolytic, and antidepressant therapies were also included as exclusion
criteria if dosage had been modified in the three months prior to the screening visit
and/or the start of the trial; as well as to suffer from any severe metabolic, hepatic, renal,
cardiovascular, neuromuscular, arthritic, pulmonary or other debilitating diseases; or to
follow any special diets in the three months prior to the start of the trial. Volunteers were
also excluded if they had suffered from eating disorders, surgically treated obesity, or if
they had a history of alcohol or drug abuse.
Before inclusion in the study, all candidates were thoroughly screened using an
extensive medical history (including blood biochemical data), resting electrocardiogram,
and blood pressure measurements, at the MU of the University of Navarra. Participants
were informed in detail about the possible risks and benefits of the study and gave their
written informed consent prior to being enrolled in the study. The intervention was
approved by the Research Ethics Committee of the University of Navarra (140/2015mod2)
and was performed in compliance with the Helsinki Declaration guidelines [39]. The study
was registered at clinicaltrials.gov as NCT03300388.
2.2. Study Design
The study was designed as a randomized double-blind placebo-controlled trial (RCT),
in which participants were allocated into four parallel intervention groups for 16 weeks:
(1) the placebo group (P) received placebo capsules containing olive oil (6 capsules of 0.5 g),
(2) the omega-3 group (n-3) received DHA-rich fish oil concentrate capsules providing
1650 mg/day of DHA and 150 mg/day of EPA as ethyl esters, with a total content of
1950 mg/day of n-3 PUFA, distributed in 6 capsules of 0.5 g of fish oil concentrate each,
(3) the placebo + resistance training group (P+RT) received 6 placebo capsules and followed
a progressive RT program of 2 sessions/week, and (4) the omega-3 + resistance training
group (n-3+RT) received the 6 DHA-rich fish oil capsules containing 1650 mg/day of DHA
and 150 mg/day of EPA, and followed a progressive RT program of 2 sessions/week.
2.3. Nutritional Intervention
Once the screening was completed, volunteers were randomly allocated to one of
the four groups using the software platform MATLAB® (The Mathworks™, Natick, MA,
USA). Randomization criteria were age and BMI according to World Health Organization
classification. Thus, the volunteers were randomized to create similar groups depending
on whether they belonged to a group of age classified as adult or older adult (55–59 and
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60–70 years old, respectively) [40]; and a BMI of overweight Grade II or obesity Type I
(27.5–29.9 and 30–35 kg/m2, respectively) [41].
At baseline and at the end of the trial, participants attended the MU at the University
of Navarra in 8–12 h fasting conditions, where anthropometric measurements, body com-
position data and blood pressure determinations were carried out by a dietitian and a
nurse. Basal fasting blood samples were then extracted in order to obtain serum/plasma to
measure biochemical parameters, and an oral glucose tolerance test (OGTT) was carried
out as described previously [42]: 75 g of anhydrous glucose (GlycoSull®, Química Clínica
Aplicada, Tarragona, Spain) were given to the volunteer and blood samples were extracted
at 30′, 60′, 90′ and 120′.
At the end of the baseline visit, volunteers were given written dietary recommenda-
tions based on the guidelines from the Spanish Society for Communitarian Nutrition (SENC,
2016) [43]. Follow up dietary consultations were scheduled every two weeks, and dietary
patterns were evaluated with a validated questionnaire of 14 items to assess adherence to
the Mediterranean diet (p14) [44] and a food frequency questionnaire (FFQ) [45] at baseline
and at the end of the study, in order to evaluate potential changes along the intervention.
When baseline visit was completed, volunteers were also given the corresponding
supplements. Subjects were asked to report any secondary effect to evaluate its possible
association with capsules consumption. Thus, once the baseline visit of the trial was com-
pleted and in every follow-up visit, all intervention groups received two boxes containing
6 blisters with 10 capsules each, for a total of 120 capsules. Participants were asked to
return boxes in every follow-up visit to evaluate adherence to supplementation by leftover
pill count.
Physical activity (PA) was also controlled with a validated PA questionnaire [46] filled
by participants at baseline and endpoint study visits. To compare PA between the four
study groups also with a direct measure, participants were asked to wear an accelerometer
(ActiGraph GT3X, Actigraph Corporation, Pensacola, FL, USA), during a random and
complete week of the study. The accelerometer was programmed for the subject’s gender,
age, weight, height, race and worn position in the body. The participants were instructed
to not change their habitual physical activity habits during the 16 weeks of the trial.
2.4. Supplements Information
Participants consumed two capsules with each meal (breakfast, lunch, and dinner).
Both placebo and DHA-rich fish oil concentrate (DHA 55%) capsules (DHAscc premium)
were provided by Solutex® (Madrid, Spain). The DHA capsules contained tocopherol
extracts as antioxidants to protect the highly unsaturated fatty acids from oxidation and
small amounts of silicon dioxide as stabilizer. The same quantity of tocopherols was added
to the olive oil capsules, although the monounsaturated fatty acids in olive oil are expected
to be more resistant to oxidation. The low amount of the other stabilizer included was
not expected to have any significant effect or modify the actions of fish oil concentrate on
health benefits. To guarantee that the DHA-rich fish oil-derived supplements were not
oxidized, peroxide and anisidine values were tested during the study and were below
maximum. Olive and fish oils were provided in hard gelatin transparent liquid fill capsules
and were similar in shape and size. Only a small difference in the thickness/color of the
oils could be appreciated.
The dose of DHA-rich fish oil-derived supplement was selected based in previous
studies [47–49], and in accordance to the U.S. Food and Drug Administration (FDA) rec-
ommendations of not exceeding 3 g/day EPA and DHA, with up to 2 g/day from dietary
supplements [50]. To fulfill these criteria, the consumption of fish was controlled depending
on their n-3 PUFA’s composition according to the European Food Safety Authority (EFSA)
recommendations for normal cardiac function (250 mg/day), based on food composition
tables from Mataix-Verdú et al. [51] and online food composition databases (Easy Diet®
and Odimet® software, Spain). Consumption of n-3-PUFA enriched food and dietary sup-
plements was not allowed during the study. Although the EFSA considers safe long-term
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consumption of EPA and DHA supplements at combined doses of up to about 5 g/day [52],
more restrictive FDA criteria were applied and therefore, not exceeding 3 g/daily intake
of EPA and DHA were allowed/considered for this trial. Fatty acid composition of the
olive oil used as placebo was analyzed as described by Ansorena et al. [53] and it is shown
in Table S1.
2.5. Resistance Training Program
After the baseline visit was completed, subjects allocated in the RT groups were
asked to assist to the Studies, Research and Sports Medicine Centre training facilities
(CEIMD), twice a week during 16 weeks of intervention, to perform dynamic resistance
exercise [54,55]. Eight exercises for upper and lower main muscular groups were included
in the training program. Two routines were designed with six exercises each: leg press,
chest press, knee extension and lat pulldown were maintained along the RT program,
while shoulder press and hip extension (Routine 1) and chest fly and leg curl (Routine 2)
were selected to complete each routine, changing every two weeks. Before testing and
training, subjects attended three sessions for familiarization with the procedure of voluntary
force production.
Strength tests were performed at the beginning, midst, and at the end of the trial
to obtain strength gains/losses data and to adjust training loads to each volunteer’s
strength. In this study, the 1-repetition maximum (1-RM) approach was used for testing [56].
Training progression was established using the pyramidal training approach, so as 50%
of intensity was selected to start the training program, and a maximum intensity of 80%
was reached at week 10 [57]. Three to four series were performed in each training session
with 8–15 repetitions adapting to training loads. In each session, one of the researchers was
present to direct and assist each subject towards ensuring adequate performance in each
exercise (work rates, loads and ranges of motion) following American College of Sports
Medicine (ACSM) guidelines for older adults.
To control for strength gains/losses also in untrained groups, first and last follow-up
visits were scheduled at the training facilities for subjects allocated to these groups in order
to perform 1-RM tests with its corresponding familiarization session. Relative strength
was calculated by dividing the maximum weight lifted in the 1-RM test (kg) to the subjects’
body weight (kg) for leg press and chest press exercises. Muscle quality was expressed
according to Pina et al. [58] as the ratio of the maximum weight lifted in the 1-RM tests (kg)
to lean soft tissue (kg) of the lower and upper limbs.
2.6. Evaluation of Weight Loss and Body Composition
The main outcome of the study was the reduction of fat mass. Body composition was
analyzed at baseline and at the end of trial by total and segmented dual X-ray absorptiome-
try (Lunar iDXA, encore 14.5, Madison, WI, USA), as previously reported [59]. Legs and
arms lean soft tissue mass changes were used as estimators of their muscle mass changes,
as previously described in aging [60] and after exercise [61]. In addition, anthropometric
measurements were obtained including arm, waist, hip, thigh, and calf circumference,
as well as arm, thigh, and calf skinfolds, following the ISAK guidelines at baseline and end
of the trial [62].
2.7. Evaluation of Lipid and Glucose Metabolism and other Biomarkers
Once basal blood samples were extracted, they were centrifuged at 1500× g for 15 min
at 4 ◦C and aliquots of serum/plasma were frozen at −80 ◦C until analysis. Fasting serum
lipid and glucose metabolism biomarkers, including total chol, HDL-chol, TG, glucose,
and OGTT timepoints’ glucose levels were determined on an autoanalyzer (Pentra C-200;
HORIBA ABX, Madrid, Spain) following manufacturer’s instructions at baseline and at the
end of the trial. LDL-chol was calculated using the Friedewald equation. Fasting insulin
was determined with an ELISA kit (#10-1132-01, Mercodia, Uppsala, Sweden) following
the manufacturer’s instructions on an autoanalyzer (Triturus ELISA Instrument, Grifols,
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Barcelona, Spain). Indexes for insulin resistance HOMA-IR and Triglycerides to Glucose
(TyG) index for insulin resistance were calculated as described previously [42].
2.8. Statistical Analysis
Considering fat mass losses as the primary outcome, based on the results reported
by previous studies on the placebo untrained group and the n-3 trained group [63,64],
the estimated effect size was 1.185. Taking a bilateral alpha of 95% and a power calculation
of 90%, the number of volunteers per group was 16. Considering a 25% of drop-out rate,
the estimated number of subjects per group would be 20.
Statistical analyses were performed using STATA, version 14. Data were expressed
as mean ± SD, and differences were significant at two-sided p value < 0.05. Possible
confounding variables were used for adjustment, and values were expressed as mean
(SEM). To select the appropriate test, normal distribution was assessed using Shapiro–Wilk
test and Breush–Pagan/Cook–Weisberg heteroscedasticity test. Comparisons between
groups at baseline were evaluated by a one-factor ANOVA test or Kruskal–Wallis test.
The comparison between baseline and endpoint within each group were assessed by paired
Student’s t-test or Wilcoxon signed-rank test as appropriate.
Due to the factorial design of the study, the statistical test two-way ANOVA was se-
lected to analyze if the changes observed after the intervention were significantly different
due to one of the two study factors, DHA-rich n-3 PUFA supplementation, RT, or by an
interaction between both. The results of the test were represented with the p value (p < 0.05)
for significant effects, or as ns for the non-significant ones, appearing below the correspond-
ing factor. Factors were named as n-3 for the DHA-rich n-3 PUFA supplementation, RT for
the exercise program, and n-3xRT for the interaction.
When statistical significance appeared at the interaction level (n-3xRT) contrasts were
performed with the aim to differentiate the group effects. If not, the significant main effects
were studied, which must be considered as (i) a main effect for supplementation (n-3)
differentiating the changes observed in the placebo groups from those observed in DHA-
supplemented groups, whether they were allocated to exercise or not; and (ii) a main effect
for exercise (RT) differentiating the changes observed in the exercised vs. the non-exercised
groups, whether they were supplemented with DHA or not.
3. Results
3.1. Basal Characteristics and Flowchart of the Participants
Of the 124 volunteers screened for the intervention, 85 initiated the trial and 71 finished
the study (Figure 1). Baseline characteristics of the study subjects were similar between
the four experimental groups, except for the basal glycemia, that was moderately lower in
the P group than in the P+RT and n-3+RT groups (Table S2). All the groups also exhibited
a similar adherence to the Mediterranean diet pattern and similar dietary fat intake and
n-6/n-3 PUFA ratio.
Although all groups reported a reduction in total fat intake at the end of the trial,
no significant changes were observed between the four intervention groups (Table S3).
Moreover, all groups showed similar PA levels, as estimated by validated questionnaires
and measured by accelerometry. Furthermore, the intervention groups did not significantly
change their PA pattern during the trial, rather than the RT expected in the allocated groups
(Table S3). Finally, the mean adherence to the RT program and supplementation (capsules
intake) was above 95% at the end of the intervention in all groups (Figure S1).
3.2. Effects on Whole Body Composition and Anthropometric Measurements
After the 16 weeks of intervention, all groups showed a moderate but statistically
significant reductions in body weight, BMI, and the percentage of fat mass (Table 1).
Visceral fat mass was also significantly reduced after the intervention in all groups except
for n-3+RT group, but a reduction was observed when adjusted for total weight loss.
Interestingly, lean mass percentage increased in the four groups after the intervention.
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However, the analysis of the changes between groups by two-way ANOVA revealed no
significant statistical differences between the four experimental groups for any of the
previously described body composition parameters.




Figure 1. Flowchart of participants from the screening to the endpoint visit of the study (16 weeks). 
In total, 85 out of the 91 women who met the inclusion criteria started the intervention. Further, 14 
participants did not complete the study (16.5% drop out), as they either discontinued follow-up due 
to unexpected health problems (n = 5, 3 unrelated to the study and 2 related to capsules consump-
tion), time incompatibilities (n = 2), withdrew from the study (n = 3), or were not compliant with the 
training sessions (n = 4). There were two dropouts in the n-3 group probably related to capsules 
consumption, one of them was related to gastroesophageal reflux and the other one related to itch 
in the hands. Dropout rates were 4.8% for P and P+RT groups, 28.6% for n-3 group and 27.3% for n-
3+RT group. For Oral Glucose Tolerance Test (OGTT) analyses, 3 subjects were excluded due to 
problems with venous insertion of the catheter in the P group, and 1 subject was excluded due to 
lack of measure at one timepoint of the glucose excursion curve in the P+RT group. DHA: Do-
cosahexaenoic Acid; PUFA: Polyunsaturated Fatty Acids. 
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the analysis of the changes between groups by two-way ANOVA revealed no significant 
statistical differences between the four experimental groups for any of the previously de-
scribed body composition parameters. 
Noteworthy, bone mineral content (BMC) significantly decreased in those groups 
that were not allocated to the RT program (Table 1). In fact, the analysis of the changes 
between groups revealed that the RT program was able to significantly prevent this re-
duction in BMC observed in the untrained groups (Table 1). 
Regarding anthropometric measurements, all groups showed a decrease in waist, 
and hip circumferences (Table 1), but the waist/hip ratio was significantly reduced only 
in the P and n-3 groups. Statistical differences were maintained in P group and appeared 
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l, 5 out of the 91 women who me the inclusion criteria started the intervention. Further,
14 participants did n t complete the study (16.5% drop out), as they either discontinued follow-
up due to unexpected health problems (n = 5, 3 unrelated to the study and 2 related to capsules
consumption), time incompatibilities (n = 2), withdrew from the study (n = 3), or were not compliant
with the training sessions (n = 4). There were two dropouts in the n-3 group probably related to
capsules consumption, one of them was related to gastroesophageal reflux and the other one related
to itch in the hands. Dropout rates were 4.8% for P and P+RT groups, 28.6% for n-3 group and
27.3% for n-3+RT group. For Oral Glucose Tolerance Test (OGTT) analyses, 3 subjects were excluded
due t problems with venous insertion of the cath ter in the P group, and 1 subject was excluded
due to l ck of measure at one timepoint of the glucose excursion curve in the P+RT group. DHA:
Docosahexaenoic Acid; PUFA: Polyunsaturated Fatty Acids.
Noteworthy, bone mineral content (BMC) significantly decreased in those groups that
were not allocated to the RT program (Table 1). In fact, the analysis of the changes between
groups revealed that the RT program was able to significantly prevent this reduction in
BMC observed in the untrained groups (Table 1).
Regarding anthropometric measurements, all groups showed a decrease in waist,
and hip circumferences (Table 1), but the waist/hip ratio was significantly reduced only in
the P and n-3 groups. Statistical differences were maintained in P group and appeared in
the n-3+RT group when adjusting for weight loss, while they disappeared in the n-3 group
(Table 1). When looking for differences in changes between groups due to RT and/or
n-3-PUFA supplementation, no significant differences were found (Table 1).
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Table 1. Effects of 16 weeks of DHA-rich n-3 PUFA (n-3) supplementation and/or resistance training (RT) on whole body
composition and anthropometric measures in overweight/obese post-menopausal women.
P n-3 P+RT n-3+RT Two-Way ANOVA c
N 20 15 20 16 n-3 RT n-3xRT
Age (years) 58.75 ± 3.39 58.00 ± 2.78 58.95 ± 3.46 58.13 ± 3.14
Weight (kg)
Baseline 76.75 ± 4.99 80.34 ± 8.51 77.76 ± 7.92 80.57 ± 6.60
Change −2.66 ± 2.95 a,*** −2.65 ± 2.47 a,** −2.21 ± 2.39 a,*** −2.70 ± 3.49 a,** ns ns ns
BMI (kg/m2)
Baseline 30.25 ± 2.30 30.39 ± 1.94 30.79 ± 2.34 31.07 ± 1.82
Change −1.07 ± 1.16 b,** −1.03 ± 0.94 a,*** −0.90 ± 0.94 a,*** −1.06 ± 1.34 a,** ns ns ns
Fat mass (%)
Baseline 47.44 ± 3.42 45.55 ± 2.38 47.05 ± 3.96 46.70 ± 2.90
Change −2.27 ± 1.14 a,*** −1.58 ± 1.34 a,*** −1.77 ± 1.50 a,*** −2.12 ± 2.40 a,** ns ns ns
Visceral fat (kg)
Baseline 1.30 ± 0.44 1.37 ± 0.44 1.27 ± 0.51 1.18 ± 0.47
Change −0.20 ± 0.19 a,*** −0.11 ± 0.14 a,** −0.11 ± 0.18 b,* −0.12 ± 0.23 a,† ns ns ns
Adjusted change d −0.20(0.04) a,*** −0.11(0.02) a,*** −0.12(0.03) b,** −0.12(0.03) a,** ns ns ns
Lean mass (%)
Baseline 49.76± 3.20 51.52 ± 2.18 50.16 ± 3.78 50.53 ± 2.76
Change 2.21 ± 1.08 a,*** 1.49 ± 1.26 a,*** 1.70 ± 1.43 a,*** 2.01 ± 2.34 a,** ns ns ns
BMC (g)
Baseline 2152.65 ± 308.05 2366.33 ± 332.76 2156.10 ± 231.21 2240.31 ± 258.36
Change −27.60 ± 17.36 *** −17.53 ± 20.22 b,** 1.40 ± 30.33 −1.38 ± 32.81 ns 0.001 ns
Adjusted change d −25.95(4.19) *** −17.50(5.08) b,** −2.08(6.63) −1.26(7.10) ns p < 0.001 ns
Waist circumference
(cm)
Baseline 93.11 ± 4.57 95.00 ± 7.63 92.67 ± 5.47 93.90 ± 7.16
Change −3.45 ± 2.62 a,*** −3.15 ± 2.94 a,** −3.01 ± 1.80 a,*** −4.04 ± 3.73 a,*** ns ns ns
Adjusted change d −3.35(0.26) a,*** −3.18(0.65) a,*** −3.08(0.38) b,*** −4.03(0.62) a,*** ns ns ns
Hip circumference
(cm)
Baseline 110.68 ± 7.14 112.50 ± 5.78 110.65 ± 5.74 113.35 ± 6.82
Change −2.40 ± 2.97 a,** −3.00 ± 3.12 a,** −3.17 ± 4.99 a,* −3.06 ± 3.52 a,** ns ns ns
Adjusted change d −2.42(0.37) a,*** −2.87(0.57) a,*** −3.33(1.17) a,* −2.89(0.91) a,** ns ns ns
Waist/hip ratio
Baseline 0.84 ± 0.04 0.85 ± 0.06 0.84 ± 0.06 0.83 ± 0.08
Change −0.01 ± 0.01 a,*** −0.01 ± 0.01 a,* −0.00 ± 0.04 −0.02 ± 0.03 ns ns ns
Adjusted change d −0.01(0.00) a,** −0.01(0.00) −0.00(0.01) −0.02(0.01) a,* ns ns ns
DHA: Docosahexaenoic Acid; PUFA: Polyunsaturated Fatty Acids; P: placebo group; n-3: DHA-rich n-3 PUFA supplemented group; P+RT:
placebo + resistance training group; n-3+RT: DHA-rich n-3 PUFA supplemented + resistance training group; BMI: body mass index; BMC:
bone mineral content. Data are mean ± SD. a Paired Student’s t-test, b Wilcoxon’s signed-rank test. c Differences between groups for
changes were evaluated by two-way ANOVA. The p value for the main factors of study, supplementation (named as n-3), exercise (named
as RT), and the interaction between both (named as n-3xRT) appears under the corresponding column. Statistical significance for a factor
establishes a main effect for such factor on differentiating the groups it classifies (n-3: n-3-supplemented vs. P-supplemented groups; RT:
RT vs. no-RT groups), according to the studied parameter. d Means (SEM) adjusted by changes in body weight. *** p < 0.001, ** p < 0.01,
* p < 0.05, † p trend (p = 0.056–0.061) vs. baseline; ns, nonsignificant (p > 0.05).
3.3. Effects on Segmented Body Composition and Anthropometric Measurements
Fat and lean mass composition as well as anthropometric measurements of arms and
legs were studied. A significant reduction in arms weight was observed only in untrained
groups after the trial. Arms lean mass tended to decrease in the non-trained groups.
Thus, the two-way ANOVA analysis suggested that the RT program significantly
prevented the lean (muscle) mass and arms weight loss compared to the untrained groups
(Table 2). Arms fat mass was reduced in the four intervention groups, although it did
not reach statistical significance in the n-3+RT group. The analysis of changes between
groups showed that the reduction in arms fat mass was significantly lower in the groups
receiving n-3 PUFA supplementation (Table 2). Nevertheless, arms circumference and
tricipital skinfold were reduced in all groups after the intervention, without significant
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differences for RT or n-3-PUFA supplementation when changes between groups were
analyzed (Table S4).
Table 2. Effects of 16 weeks of DHA-rich n-3 PUFA (n-3) supplementation and/or resistance training (RT) on segmented
body composition and anthropometric measures in overweight/obese postmenopausal women.
P n-3 P+RT n-3+RT Two-Way ANOVA c
N 20 15 20 16 n-3 RT n-3xRT
Arms weight (kg)
Baseline 8.65 ± 0.89 8.60 ± 1.17 8.73 ± 1.21 8.83 ± 1.04
Change −0.37 ± 0.40 a,*** −0.33 ± 0.42 a,** −0.13 ± 0.40 0.01 ± 0.60 ns 0.010 ns
Adjusted change d −0.38(0.07) a,*** −0.32(0.11) a,* −0.15(0.09) 0.02(0.11) ns 0.003 ns
Arms fat mass (kg)
Baseline 4.36 ± 0.60 4.01 ± 0.68 4.32 ± 0.68 4.24 ± 0.71
Change −0.33 ± 0.27 a,*** −0.24 ± 0.24 b,** −0.22 ± 0.28 a,** −0.11 ± 0.41 ns ns ns
Adjusted change d −0.34(0.04) a,*** −0.23(0.06) a,** −0.24(0.05) a,*** −0.10(0.07) 0.041 ns ns
Arms lean mass (kg)
Baseline 4.02 ± 0.56 4.30 ± 0.60 4.13 ± 0.66 4.29 ± 0.47
Change −0.04 ± 0.18 −0.09 ± 0.22 0.09 ± 0.19 a,† 0.13 ± 0.30 ns 0.002 ns
Adjusted change d −0.05(0.04) −0.09(0.06) 0.09(0.04) a,† 0.13(0.07) a,† ns 0.002 ns
Legs weight (kg)
Baseline 25.10 ± 3.59 27.52 ± 3.28 26.55 ± 3.91 27.11 ± 3.95
Change −0.60 ± 1.79 b,† −0.91 ± 0.97 a,** −0.95 ± 1.12 a,** −0.98 ± 1.45 a,* ns ns ns
Adjusted change d −0.51(0.22) b,** −0.86(0.10) a,*** −1.08(0.22) a,*** −0.91(0.10) a,*** ns ns ns
Legs fat mass (kg)
Baseline 11.29 ± 2.58 12.16 ± 2.38 12.36 ± 2.88 12.18 ± 2.47
Change −0.62 ± 0.90 b,** −0.73 ± 0.66 a,*** −0.96 ± 0.73 a,*** −0.97 ± 1.02 a,** ns ns ns
Adjusted change d −0.60(0.12) b,** −0.70(0.08) a,*** −1.02(0.14) a,*** −0.92(0.12) a,*** ns 0.005 ns
Legs lean mass (kg)
Baseline 13.03 ± 1.57 14.51 ± 1.66 13.40 ± 1.64 14.11 ± 1.88
Change 0.02 ± 0.98 −0.16 ± 0.50 0.02 ± 0.57 0.02 ± 0.63 ns ns ns
Adjusted change d 0.01(0.14) −0.15(0.10) −0.05(0.13) 0.03(0.99) ns ns ns
Thigh circumference (cm)
Baseline 56.42 ± 4.54 56.75 ± 3.48 59.71 ± 5.21 60.42 ± 6.42
Change −1.49 ± 1.75 b,** −0.84 ± 1.18 a,* −2.38 ± 3.00 a,** −1.50 ± 2.52 a,* ns ns ns
Adjusted change d −1.07(0.24) b,** −0.91(0.40) a,* −2.71(0.57) a,*** −1.60(0.56) a,* ns ns ns
Calf circumference (cm)
Baseline 38.05 ± 2.12 39.59 ± 2.58 40.15 ± 2.41 39.30 ± 2.55
Change −0.32 ± 0.54 a,* −0.39 ± 0.67 a,* −0.81 ± 0.78 b,*** −0.68 ± 0.69 a,** ns 0.017 ns
Adjusted change d −0.26(0.09) a,* −0.38(0.15) b,* −0.85(0.19) a,*** −0.68(0.13) a,*** ns 0.005 ns
Thigh skinfold (mm)
Baseline 39.92 ± 4.76 41.25 ± 5.49 42.67 ± 2.99 41.06 ± 5.37
Change 0.43 ± 3.36 −1.23 ± 2.28 b,* −3.43 ± 3.15 a,*** −5.19 ± 7.61 b,** ns p < 0.001 ns
Adjusted change d −0.28(0.61) −0.70(0.54) b,* −3.31(0.66) a,*** −4.64(1.92) b,* ns p < 0.001 ns
Calf skinfold (mm)
Baseline 31.07 ± 5.28 32.02 ± 5.60 33.26 ± 4.88 34.76 ± 5.45
Change −1.26 ± 3.65 −2.51 ± 3.05 a,** −5.17 ± 4.63 a,*** −7.73 ± 7.40 b,** ns p < 0.001 ns
Adjusted change d −1.46(0.70) a,† −2.25(0.80) a,* −5.05(1.92) a,*** −7.44(1.82) b,** ns p < 0.001 ns
DHA: Docosahexaenoic Acid; PUFA: Polyunsaturated Fatty Acids; P: placebo group; n-3: DHA-rich n-3 PUFA supplemented group;
P+RT: placebo + resistance training group; n-3+RT: DHA-rich n-3 PUFA supplemented + resistance training group. Data are mean ± SD.
a Paired Student’s t-test, b Wilcoxon’s signed-rank test. c Differences between groups for changes were evaluated by two-way ANOVA.
The p value for the main factors of study, supplementation (named as n-3), exercise (named as RT), and the interaction between both
(named as n-3xRT) appears under the corresponding column. Statistical significance for a factor establishes a main effect for such factor on
differentiating the groups it classifies (n-3: n-3-supplemented vs. P-supplemented groups; RT: RT vs. no-RT groups), according to the
studied parameter. d Means (SEM) adjusted by changes in body weight. *** p < 0.001, ** p < 0.01, * p < 0.05, † p trend (p = 0.052–0.061) vs.
baseline; ns, nonsignificant (p > 0.05).
Regarding lower body composition, legs weight was reduced in all intervention
groups (Table 2). Although reductions tended to be higher in RT vs. untrained groups,
two-way ANOVA did not reach statistical significance (p = 0.098). Legs lean mass did
not change in any of the intervention groups, neither when baseline-endpoint nor when
changes between groups were analyzed. Nevertheless, legs fat mass did decrease in the four
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groups of study, with a significantly higher decrease in the RT vs. the non-trained groups.
Anthropometric measurements reflected similar results, as calf circumference was reduced
in all study groups, with significantly higher losses only in RT groups when changes
between groups were compared (Table 2). Thigh circumference was also moderately
reduced in the four experimental groups but did not change significantly by either RT or n-3-
PUFA supplementation when analyzed by two-way ANOVA. Similar to calf circumference,
calf and thigh skinfolds reductions were significantly higher in the RT groups compared to
the untrained groups (Table 2).
3.4. Effects on Muscle Strength and Quality
Muscle strength values (kg, 1-RM tests) were normalized to the subjects’ body weight
at baseline and at the end of the trial. Likewise, muscle quality was calculated as previously
described [58] for both upper and lower limbs, by dividing muscle strength (kg lifted in the
chest and leg press 1-RM tests)/lean mass (kg measured in arms and legs DXA segmented
analyses). As expected, the RT groups significantly increased their muscle strength and quality
(p < 0.001) compared to the untrained groups, both in upper and lower limbs (Figure 2).
Noteworthy, the DHA-rich supplement did not influence muscle strength but revealed
a tendency to promote this effect in lower limbs (p = 0.067) that could rely on the local
improvement in muscle quality (p < 0.01). However, these effects observed in lower limbs
by n-3 PUFA supplementation were not mimicked by the results observed in the upper
limbs. No synergistic effects were observed for the DHA-rich supplementation on strength
and muscle quality gains derived from the RT program.
3.5. Effects on Blood Pressure and Lipid Metabolism Biomarkers
With respect to blood pressure measurements, systolic and diastolic blood pressure
did not show significant changes in any group except for a significant reduction in diastolic
blood pressure in the n-3+RT group (Table 3).
However, two-way ANOVA revealed a significant effect for the DHA-rich supplement
on lowering diastolic blood pressure in n-3 compared to P-supplemented groups. TG were
significantly reduced after the intervention in all groups, except the P group.
The analysis of the differences of changes between groups showed that this reduction
in TG was significantly higher in the n-3 supplemented groups as compared with those
receiving placebo (Table 3). Total chol and LDL-chol were reduced only in P+RT group after
the intervention, but when values were adjusted for fat mass loss and the corresponding
baseline value, this effect was also observed in the P group. However, when comparing
the differences between groups, no statistical differences were found for the changes in
cholesterol parameters (Table 3).
3.6. Effects on Serum Glucose Metabolism Biomarkers
Fasting glucose tended to decrease in all intervention groups, but without statistical
significance in any of them when comparing baseline-endpoint values (only a significant
reduction was observed in the n-3+RT group after adjusting by changes in fat mass and
values at baseline). However, no statistically differences were observed when changes
between groups were compared by two-way ANOVA (Table 3).
Fasting insulin and HOMA-IR index were significantly reduced in P-supplemented
and n-3+RT groups after the intervention (after adjusting by changes in fat mass and values
at baseline, a significant decrease in fasting insulin and HOMA-IR was also observed
in the P+RT group). However, no significant differences induced by RT or n-3-PUFA
supplementation were observed when the changes between groups were analyzed (Table 3).
The TyG index, a reliable marker for insulin resistance, was significantly reduced after the
intervention in both groups performing the RT program (P+RT and n-3+RT); yet, when the
differences in changes between the intervention groups were evaluated, no significant
effects were reached (Table 3).
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Figure 2. Effects of 16 weeks of DHA-rich n-3 PUFA (n-3) supplementation and/or resistance training
(RT) on upper limbs (left panels) and lower limbs (right panels) muscle strength (A) and muscle
quality (B). Muscle strength was calculated as 1-RM (kg)/body weight (kg); and muscle quality,
as 1-RM (kg)/local lean mass (kg). Baseline-endpoint differences (joined dots graphs) were studied
by paired Student’s t-test or Wilcoxon’s signed-rank test after testing for normality. *** p < 0.001;
** p < 0.01; * p < 0.05 vs. baseline. Differences in changes between groups (bar graphs) were
compared by two-way ANOVA. When a significant effect was found for one of the main factors
of study, the p value was represented under the c responding factor in the legend appearing
above the graph. Factors were name as n-3 f DHA-rich -3 PUFA supplemen ation, RT for
ex cise, and n-3xRT the interaction between both. Statistical significance for a factor establishes
a m in effect for such factor on differentiati g the groups it classifi (n-3: n-3-supplemented
vs. P-supplemented gro s; RT: RT vs. no-RT groups) according to the studied parameter (ns,
nonsignificant, p > 0.05). Data are mean ± SEM. P: placebo group, n-3: DHA-rich n-3 PUFA
supplemented group; P+RT: placebo + resistance training group; n-3+RT: DHA-rich n-3 PUFA
supplemented + resistance training group.
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Table 3. Effects of 16 weeks of DHA-rich n-3 PUFA (n-3) supplementation and/or resistance training (RT) on blood pressure
and glucose and lipid metabolism biomarkers in overweight/obese postmenopausal women.
P n-3 P+RT n-3+RT Two-Way ANOVA c
N 20 15 20 16 n-3 RT n-3xRT
SBP (mm Hg)
Baseline 121.83 ± 19.68 119.18 ± 7.98 122.73 ± 14.96 123.67 ± 9.01 ns ns ns
Change −2.40 ± 10.84 0.20 ± 10.96 −1.22 ± 14.45 −6.00 ± 11.79 ns ns ns
DBP (mm Hg)
Baseline 80.04 ± 12.38 79.71 ± 6.05 79.08 ± 7.88 81.62 ± 6.67 ns ns ns
Change −1.40 ± 7.13 −2.09 ± 6.97 1.83 ± 7.05 −4.94 ± 7.70 a,* 0.035 ns ns
TG (mg/dL)
Baseline 92.64 ± 29.47 118.20 ± 55.31 110.90 ± 51.66 101.34 ± 33.26
Change 1.94 ± 26.29 −28.87 ± 52.97 b,* −17.10 ± 23.78 b,* −18.88 ± 28.73 b,* 0.047 ns ns
Adjusted change d 2.99(6.14) −22.09(7.34) a,** −13.98(4.02) a,** −20.75(5.06) a,** 0.038 ns ns
Total Chol (mg/dL)
Baseline 237.40 ± 30.79 239.73 ± 46.41 254.50 ± 27.83 250.31 ± 45.89
Change −8.10 ± 25.20 −9.00 ± 44.86 −21.45 ± 24.34 b,** −14.41 ± 43.32 ns ns ns
Adjusted change d −12.66(4.87) a,* −12.66(8.06) −17.42(3.83) a,*** −10.41(8.62) ns ns ns
LDL−Chol (mg/dL)
Baseline 153.31 ± 32.65 154.20 ± 36.89 168.40 ± 24.49 164.90 ± 44.04
Change −6.98 ± 19.29 −4.22 ± 35.87 −14.20 ± 23.09 b,** −8.14 ± 38.54 ns ns ns
Adjusted change d −10.46(3.65) a,* −7.79(7.47) −10.69(3.95) a,* −5.29(7.60) ns ns ns
HDL−Chol (mg/dL)
Baseline 65.74 ± 16.77 61.89 ± 16.38 63.92 ± 14.61 65.15 ± 11.03
Change −0.55 ± 9.45 −0.99 ± 13.97 −3.83 ± 8.32 a,† −2.50 ± 9.46 ns ns ns
Adjusted change d −0.08(1.70) −0.07(2.68) −4.35(1.83) a,* −1.63(2.08) ns ns ns
Glucose (mg/dL)
Baseline 98.57 ± 13.03 103.90 ± 15.72 109.14 ± 18.90 108.35 ± 11.32
Change −1.83 ± 9.22 −0.86 ± 11.87 −3.59 ± 20.78 −4.73 ± 9.36 a,† ns ns ns
Adjusted change d −3.60(2.82) −2.53(2.67) −1.33(1.52) −3.83(1.52) a,* ns ns ns
Insulin (mU/L)
Baseline 10.02 ± 4.41 9.90 ± 5.21 9.49 ± 5.00 10.54 ± 4.05
Change −2.63 ± 3.91 b,* −0.84 ± 2.75 −1.35 ± 4.03 −1.96 ± 2.76 b,* ns ns ns
Adjusted change d −2.28(0.63) a,** −1.01(0.75) −1.83(0.63) a,** −1.75(0.49) a,* ns ns ns
HOMA−IR index
Baseline 2.51 ± 1.43 2.48 ± 1.19 2.67 ± 1.86 2.82 ± 1.14
Change −0.71 ± 1.05 b,* −0.23 ± 0.87 −0.54 ± 1.52 −0.60 ± 0.74 b,** ns ns ns
Adjusted change d −0.63(0.15) a,*** −0.40(0.21) a,† −0.56(0.17) a,** −0.53(0.13) a,** ns ns ns
TyG index
Baseline 8.45 ± 0.45 8.64 ± 0.41 8.64 ± 0.47 8.59 ± 0.39
Change −0.05 ± 0.31 −0.15 ± 0.37 −0.17 ± 0.27 a,* −0.23 ± 0.33 a,* ns ns ns
Adjusted change d −0.08(0.07) −0.13(0.09) −0.16(0.06) a,* −0.22(0.06) a,** ns ns ns
DHA: Docosahexaenoic Acid; PUFA: Polyunsaturated Fatty Acids; P: placebo group, n-3: DHA-rich n-3 PUFA supplemented group; P+RT:
placebo + resistance training group; n-3+RT: DHA-rich n-3 PUFA supplemented + resistance training group; SBP: systolic blood pressure;
DBP: diastolic blood pressure; TG: triglycerides; Total Chol: total cholesterol; HDL-Chol: HDL-cholesterol; LDL-Chol: LDL-cholesterol; TyG:
triglycerides to glucose index. Data are mean ± SD. a Paired Student’s t-test, b Wilcoxon’s signed-rank test. c Differences between groups
for changes were evaluated by two-way ANOVA. The p value for the main factors of study, supplementation (named as n-3), exercise
(named as RT), and the interaction between both (named as n-3xRT) appears under the corresponding column. Statistical significance for a
factor establishes a main effect for such factor on differentiating the groups it classifies (n-3: n-3-supplemented vs. P-supplemented groups;
RT: RT vs. no-RT groups), according to the studied parameter. d Means (SEM) adjusted by changes in fat mass and values at baseline.
*** p < 0.001, ** p < 0.01, * p < 0.05, † p trend (p = 0.053–0.062) vs. baseline; ns, nonsignificant (p > 0.05).
The effect of a 16-week RT program alone or in combination with DHA supplementa-
tion on glucose tolerance was also studied through an OGTT. For that, a high-glucose bev-
erage (75 g) was administered to the volunteers in order to evaluate the changes in serum
glucose. The glucose excursions after OGTT are represented in Figure 3A, which shows the
levels before and after the intervention in the four study groups. After the intervention,
all groups, except the n-3 group, exhibited a better response to the OGTT than at baseline.
However, when the areas under the curves (AUC) were calculated, only a significant
reduction when comparing before and after was found in the P+RT group, and a tendency
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to decrease was observed in n-3+RT group. To adjust for basal glucose, iAUC was also
calculated, with significant reductions in the P+RT group. When differential changes
between groups were analyzed by two-way ANOVA, the AUC showed a tendency to
decrease in RT groups (p = 0.066), and a significant decrease in iAUC was found in RT
groups vs. not trained groups (Figure 3B,C). Nevertheless, the DHA supplementation had
no remarkable effect on any of the glucose tolerance parameters analyzed.
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Comparisons between baseline and endpoint values (A) were assessed using paired Student’s t-test or Wilcoxon’s signed-
rank test. * p < 0.05, ** p < 0.01, † p = 0.060 vs. baseline. Comparison of changes in AUC (B) and iAUC (C) between groups
was evaluated by two-way ANOVA. When a significant effect was found for one of the main factors of study, the p value
was represented under the corresponding factor in the legend appearing above the graph. Factors were named as n-3 for
DHA-rich n-3 PUFA supplementation, RT for exercise, and n-3xRT for the interaction between both. Statistical significance
for a factor establishes a main effect for such factor on differentiating the groups it classifies (n-3: n-3-supplemented vs.
P-supplemented groups; RT: RT vs. no-RT groups) according to the studied parameter (ns, nonsignificant, p > 0.05). Data are
mean ± SEM. P: placebo group, n-3: DHA-rich n-3 PUFA supplemented group; P+RT: placebo + resistance training group;
n-3+RT: DHA-rich n-3 PUFA supplemented + resistance training group; AUC: area under curve, iAUC: incremental AUC.
4. Discussion
Here, we describe the effects of a 16-week intervention with a DHA-rich supplement
combined or not with a RT program on body composition, serum glucose and lipid
metabolism biomarkers, blood pressure and muscle strength and quality in overweight and
obese postmenopausal women. While few previous studies in postmenopausal women
have combined n-3 PUFA supplementation and RT, these trials were focused on muscle
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metabolism, strength and function; and some lacked either a placebo group, or an untrained
group [23–26].
In the present study, the four experimental groups showed moderate but significant
reductions in body weight, BMI, and fat percentage, along with lower visceral adipose
tissue, and waist and hip circumferences after the intervention. These results suggest the
efficacy of dietary advice for a healthy diet on remodeling body composition without a
hypocaloric dietary approach. It should be considered that several studies have suggested
that olive oil supplementation, the placebo used in our trial, can also promote moderate
weight loss [65]. However, the amount of olive oil supplemented (3.0 g/day) was equiva-
lent to approximately less than 10% daily recommendations for the Spanish population
(45 g/day) [43]. Therefore, it is unlikely that the olive oil-based placebo supplement might
have contributed to the unexpected weight loss observed in the placebo groups.
On the other hand, our data in the RT groups may apparently contrast with previous
studies observing effects for RT on inducing fat mass loss in adults as compared to non-trained
subjects [15,19]. However, RT effects in postmenopausal women without dietary treatment only
had such effects in body composition when longer intervention periods [20,66], higher training
volumes [9,23,26], groups mixing women and men [14,19,67,68], or only overweight or few
proportions of obese women were included [18,66,69]. Even in those circumstances, no effects
in body composition have been reported in postmenopausal women [11–13].
The lack of effects for RT on whole-body muscle mass, namely fat free mass or lean
mass, has been reported in postmenopausal women [11–13,21]. Similar to those showing
effects on adiposity, those reporting effects on increasing muscle mass used rather long
exercise protocols, applied higher training volumes, mixed men and women, or were per-
formed only in overweight subjects [9,19,25,70,71]. Here, we provide evidence of a 16-week
protocol that achieved muscle strength and quality gains, alongside high adherence rates
(above 95%), with a moderate RT program (10 out of 16 weeks with 70–80% RM loads)
in previously untrained, overweight, and obese post-menopausal women. Others have
reported increased muscle strength, quality, cross sectional area or muscle protein synthesis
that were not translated to higher muscle mass in older populations nor in postmenopausal
women [9,12,13,72]. Noteworthy, Churchward-Venne et al. [73] compared two different
training programs in older overweight women and concluded that, although there are no
non-responders to exercise, the time-effect response is highly individualized. Similarly,
Ahtiainen et al. [19] collected studies of their group developing the same RT program
in different populations and observed a large interindividual variations in the training
response that could not be explained by sex, age, body composition or nutritional status.
Therefore, the physiological adaptations secondary to RT might rely on individual features
whose causative role are beyond the purpose of this study.
Analyses of upper and lower body composition by DXA segmented analyses revealed
principal effects for the RT program when studying changes among groups. In upper
limbs, our RT program suggested effects on arms muscle hypertrophy and weight mainte-
nance compared to the untrained groups, who showed a moderate weight and lean mass
losses. To our knowledge, it is the first time these effects of RT compared to untrained
postmenopausal women are reported in the literature with shorter training programs, as im-
provements in segmented muscle mass have been reported previously only for overweight
older women and longer training periods and/or higher frequencies [20,58]. Regarding
lower body composition, RT did not show an effect in legs weight and lean (muscle) mass,
but it did increase fat mass loss as compared to untrained groups. Such effects could be
explained by women’s natural distribution of adiposity in gluteofemoral areas, and thus
could be the main effect of our RT program on fat mass losses. In fact, those studies
reporting increases in lower limbs lean mass after RT were conducted in leaner women [21],
and no differences have been reported on lower limbs fat mass [21,23,58]. Anthropometric
measurements results agreed with those found in DXA for lower limbs body composition,
as RT had a significant effect in decreasing leg skinfolds and calf circumference as compared
to untrained groups. On the contrary, thigh circumference did not change with RT, indi-
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cating a possible hypertrophy in thighs and higher fat mass losses at calves. Upper limbs
anthropometric measurements did match those of DXA regarding arms hypertrophy with
RT, as arms circumference did not change. Thus, these results support that segmented
body composition changes measured by DXA were comparable to those obtained with the
anthropometric measurements including the observed upper limbs hypertrophy and lower
limbs fat mass loss after RT. Moreover, these results establish anthropometry as a reliable
tool for evaluating changes in upper and lower body composition in overweight/obese
postmenopausal women under exercise programs.
Findings of RT effects improving upper limbs muscle (lean) mass, as well as upper
and lower limbs muscle quality and strength were consistent with resistance training
improving also whole-body BMC. A clear effect of RT on BMC maintenance was observed,
despite small changes and high variability. However, there were no effects on bone mineral
density (BMD) (data not shown). Data of exercise programs effects on bone metabolism in
postmenopausal women are large, and thus several meta-analyses have been conducted,
concluding that combined RT and high impact exercises are the best to maintain BMD
after longer interventional periods [10], while local effects of RT on BMD have also been
observed [74]. Although BMC results can be found in trials, such results were not included
in the statistical analyses of such meta-analyses. In fact, BMC has less clinical relevance
compared to BMD, and thus studies of BMC changes in postmenopausal women after
RT are lacking. Despite this, both BMD and BMC are predictors of fracture risk [75].
BMC improvements without concomitant effects on BMD after RT in postmenopausal
women with low bone mass have been reported before [76]. Thus, our finding supports
a beneficial effect of RT on bone mass independent of n-3-PUFA supplementation and
regardless of having or not low BMD and BMC in a population at risk of bone mass
loss. In fact, recent studies investigating the effects of RT in postmenopausal women
revealed local increments in femoral BMC that occurred together with an increase in bone
thickness [77]. In turn, bone thickness is strongly related to an increment in the femoral
neck fracture load [78], which is defined as the load which is great enough to break the bone,
and thus could be understood as bone resistance to fracture. Furthermore, BMC has even
been proposed for the clinical diagnose of osteoporosis besides BMD [79], being the first a
proxy of bone geometry and the latter of bone quality, both relevant for the maintenance of
a healthy bone structure.
As expected, no effects were observed for n-3 PUFA supplementation alone or com-
bined with RT on body composition changes [37]. Other groups have observed similar
results to ours using DHA and EPA at similar doses (1.62 g/day, 1.9:1 DHA:EPA) [48,49].
Such studies did not show differences between the placebo (6 capsules x 1g Sunola oil
per day) and fish oil supplemented group in any of the body weight and composition
parameters after 12 weeks of supplementation [48], neither when combining it with a
very low energy diet [49]. Surprisingly, a significant effect of n-3-PUFA supplementation
was found for smaller fat mass losses in arms than placebo supplementation. Conversely,
these effects were not translated to smaller subcutaneous fat mass losses, as both tricipital
skinfold and arm circumference decreased in the four groups of study without differences
in changes. In fact, it has been described that the main synergistic effects of n-3 PUFA to
RT on body composition are the promotion of muscular protein synthesis together with
beneficial effects on the neuromuscular system [24,80], with no further effects on body
composition. With this regard, our results showed effects for RT on increasing muscular
strength and quality significantly in lower and upper limbs, while n-3 PUFA revealed an
effect on muscle quality in lower limbs. Such effects are supported by those observed by
Rodacki et al. [26] and Strandberg et al. [25], who showed increased activation and neuro-
muscular response to RT in groups supplemented with n-3-PUFA (2 g, EPA 29.5± 0.7% and
DHA 23.6 ± 0.2%, for 90 or 150 days) or with a n-3 PUFA enriched diet (ratio n-6/n-3 < 2,
24 weeks) respectively, coupled to a RT program. It must be noted that their RT programs
used high training intensities for longer training periods (80% of 1-RM for 10 and 20 weeks),
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and that subjects were leaner than those included in our study, according to BMI (mean
BMI ~24.7–27.7 kg/m2).
The DHA-rich n-3 PUFA supplementation exerted two remarkable effects in main
cardiovascular risk factors, blood pressure and circulating lipids. Firstly, diastolic blood
pressure was reduced by the DHA-rich supplementation when compared to the placebo
supplementation. This result is in line with others who have observed inverse associations
between erythrocyte DHA content and hypertension in postmenopausal women [33,81].
Although a recent trial in middle aged women showed no results after n-3 PUFA sup-
plementation with similar DHA dose to those used in our study, a smaller sample size
(n = 6, 1600 mg DHA + 400 mg EPA) was studied [82]. On the other hand and similar
to what has been demonstrated in older subjects and in postmenopausal women [33,83],
the DHA-rich n-3 PUFA supplementation also induced a reduction in circulating TG,
which is in agreement with the recognized n-3 PUFA hypotriglyceridemic claimed effects.
Concerning total chol, LDL-chol and HDL-chol no effects were observed for the DHA-
rich supplementation on improving their levels when compared to the placebo groups,
nor when comparing within groups. Accordingly, a recent meta-analysis concluded that
n-3 PUFA exert effects only in lowering TG [83]. These effects of DHA supplementation
on cardiovascular risk factors are especially relevant in the postmenopausal population,
in which cardiovascular-mortality exhibits a sudden rise [84].
Regarding the RT program, no effects were observed on any of the cardiovascular
risk parameters when comparing trained groups to untrained groups, although circulating
levels of Total chol, LDL-chol and HDL-chol were decreased in the P+RT group, and both
trained groups revealed a decrease in TG. Despite the recent meta-analyses describing ben-
eficial effects of RT on circulating lipid levels in adults [15,85], multiple trials investigating
RT effects on blood lipid levels observed no effects in postmenopausal women and older
adults [19,21,68,86]. Thus, several studies have assessed this question by examining the
individual response to RT in older adults. Although the occurrence of non-responders
to RT was discarded recently [73,87], the individual response to RT was quantified in
the aforementioned studies and described to be highly heterogeneous, leading to a great
variability in the measured outcomes especially in blood lipids [19,73], as observed in our
n-3+RT group. On the other hand, the presence of subjects with delayed time-response
effect might have led to little changes in body composition [67,73], that in turn mediate
circulating lipid levels [69,88]. Nevertheless, it seems that the most consistent outcome
of RT in blood lipid levels in older adults and postmenopausal women is the increase in
HDL-chol, even when the rest of lipids do not change [19,67,89]. By contrast, our HDL-chol
levels were decreased in both trained groups and significantly in P+RT group, possibly due
to the higher levels at baseline observed in our participants compared to those participating
in the aforementioned trials. Moreover, such levels could be a consequence of increased
levels of the atherogenic HDL-chol fraction.
A remarkable effect exerted by RT was the improvement in glucose tolerance. Thus,
RT groups showed an effect in OGTT-iAUC compared to untrained groups, regardless
of n-3-PUFA supplementation. These effects of RT on improving glucose tolerance in
postmenopausal women can rely on the local increases in muscle (lean) mass and the
muscle strength and quality gains. In fact, sarcopenic older subjects under RT exhibited
lower glucose AUC after the intervention [90], demonstrating muscle’s essential role in
glucose metabolism. However, the improved glucose tolerance was not accompanied by
similar outcomes in fasting glucose, insulin, and HOMA-IR index, although small but
significant improvements were observed in TyG index for insulin resistance in both trained
groups. Insulin sensitivity measurements are lacking in this study, but it might be the
causative factor for the improved glucose metabolism and TyG index, regardless of fasting
insulin and HOMA-IR levels, and secondary to the increased glucose tolerance. In fact,
RT has been shown to have lower effects on insulin resistance as compared to aerobic or
combined (resistance + aerobic) training [14] which are, in turn, demonstrated to elicit
higher fat mass losses [91]. Moreover, the higher variability in responses to the intervention
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observed in the n3-PUFA+RT group may have blunted both RT and n-3 PUFA principal
effects when changes between groups were studied. Nevertheless, it has to be noted that
lack of synergistic effects for RT and fish oil supplementation on fasting glucose and insulin
was also observed in postmenopausal women in the study of Da Boit et al. [24].
There are limitations in the current study that need to be considered. Some previous
clinical trials with n-3 PUFA derived from fish oil have reported difficulties to successful
blinding because of the fishy taste and odor of these fatty acids [92]. We must report a
difficulty with the double blinding of our study, due to the fishy taste reported by some
of the participants allocated in the DHA-rich supplement groups and a small difference
in the thickness/color of the olive oil (placebo) and the fish oil concentrate, as they were
provided in transparent liquid fill capsules. Although some of the investigators providing
the capsules to the volunteers suspect about the type of supplements, most of the partic-
ipants were blinded concerning the type of supplement they were receiving. Moreover,
the researchers in charge to carry out the biochemical analysis of the blood samples and
DXA analysis were totally blinded and therefore we consider that this minor incident with
the blinding has not affected the results reported in this study.
Another limitation of the study is that we had few participants between 65–70 years,
and the mean ages of subjects were closer to the middle-age, and thus interrelationships
between obesity and menopause may have had a more relevant role than expected in
the response to both RT and n-3-PUFA supplementation. Moreover, evidence in the
current literature for both RT and n-3-PUFA interventions in postmenopausal women
is largely heterogenous regarding methodologies conducted and characteristics of the
study populations, making it difficult to compare effects between studies. These facts and
the applicability of the findings obtained in the present study highlight the relevance of
performing future trials involving a higher number of postmenopausal older women.
5. Conclusions
In summary, our data suggest that progressive intensity RT has beneficial effects on
upper limbs muscular hypertrophy and lower limbs fat mass loss, on muscle strength and
muscle quality, along with whole body BMC maintenance and improved glucose tolerance
in postmenopausal women. The DHA-rich oil supplement had the previously documented
effect on lowering fasting TG levels and lowered diastolic blood pressure. However,
no effects were found on insulin resistance or other biomarkers of lipid metabolism, and no
relevant synergistic effects for n-3-PUFA and RT were observed.
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